Oppenheimer began coverage on shares of Viking Therapeutics (NASDAQ:VKTX) in a research note issued to investors on Tuesday, BenzingaRatingsTable reports. The firm issued an outperform rating and a $12.00 price target on the biotechnology company’s stock. Oppenheimer also issued estimates for Viking Therapeutics’ Q2 2019 earnings at ($0.09) EPS, Q3 2019 earnings at ($0.12) EPS, Q4 2019 earnings at ($0.15) EPS, FY2019 earnings at ($0.43) EPS, FY2020 earnings at ($0.56) EPS, FY2021 earnings at ($0.74) EPS, FY2022 earnings at ($1.02) EPS and FY2023 earnings at ($1.38) EPS.
Other equities analysts also recently issued research reports about the company. BidaskClub downgraded Extraction Oil & Gas from a hold rating to a sell rating in a report on Saturday, May 4th. Citigroup set a $12.00 price objective on Controladora Vuela Co Avcn SA CV and gave the stock a buy rating in a report on Monday. William Blair restated an outperform rating on shares of Accenture in a report on Friday, March 29th. Stifel Nicolaus assumed coverage on GENFIT S A/ADR in a report on Tuesday, June 25th. They issued a hold rating on the stock. Finally, HC Wainwright restated a buy rating and issued a $31.00 price objective on shares of Viking Therapeutics in a report on Thursday, April 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Viking Therapeutics presently has an average rating of Buy and an average price target of $20.53.
Shares of VKTX opened at $8.43 on Tuesday. The firm has a market cap of $594.39 million, a P/E ratio of -21.08 and a beta of 2.30. Viking Therapeutics has a fifty-two week low of $6.97 and a fifty-two week high of $24.00. The firm has a 50-day simple moving average of $8.07.
A number of large investors have recently added to or reduced their stakes in VKTX. Rubric Capital Management LP bought a new stake in Viking Therapeutics during the first quarter worth approximately $8,051,000. BlackRock Inc. boosted its position in Viking Therapeutics by 22.4% during the fourth quarter. BlackRock Inc. now owns 4,099,406 shares of the biotechnology company’s stock worth $31,361,000 after purchasing an additional 749,505 shares during the period. Park West Asset Management LLC boosted its position in Viking Therapeutics by 31.8% during the fourth quarter. Park West Asset Management LLC now owns 1,672,507 shares of the biotechnology company’s stock worth $12,794,000 after purchasing an additional 403,400 shares during the period. Two Sigma Investments LP bought a new stake in Viking Therapeutics during the fourth quarter worth approximately $2,981,000. Finally, New York State Common Retirement Fund boosted its position in Viking Therapeutics by 263.7% during the fourth quarter. New York State Common Retirement Fund now owns 336,377 shares of the biotechnology company’s stock worth $2,573,000 after purchasing an additional 243,897 shares during the period. Hedge funds and other institutional investors own 63.53% of the company’s stock.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.
Read More: What is a closed-end mutual fund (CEF)?
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.